Skip to content
Medical Health Aged Care

A natural breakthrough in protecting cereals and field crops

Amoeba 5 mins read

Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK

Chassieu, France Basel, Switzerland , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Amoebas. These single-celled microorganisms are now at the heart of one of agriculture’s latest biological innovation – a bio-fungicide capable of protecting wheat and other cereal crops from crippling fungal diseases that cost global agriculture billions of dollars in annual crop losses and quality.

This new development, made from the lysate of the amoeba Willaertia magna C2c Maky, holds strong potential to advance biological crop protection. In trials, the candidate demonstrated its effectiveness in combating the fungi responsible for these fungal diseases and helped activate the plants' defence responses. As a next‑generation biological, it is built on a biological active substance and designed to fit modern integrated crop management.  

Syngenta Crop Protection, a global leader in biologicals and other innovative crop protection technologies, and French greentech innovator Amoéba SA, have now signed a Memorandum of Understanding to develop and commercialize groundbreaking biocontrol solutions for the EU and UK markets, focusing on cereals and field crops. The parties plan to negotiate a definitive distribution agreement with a target timeline of spring 2026.This strategic collaboration aims to offer farmers advanced biological solutions that enhance the sustainability of their farming practices, address the challenge of increasing pest resistance to existing products, and offer relief to farmers facing a shrinking toolbox of crop protection technologies.

The initial focus of the partnership will be on combating the main wheat diseases, namely septoria tritici blotch (STB) and yellow rust. These two diseases are among the most economically damaging wheat diseases across Europe and the UK, impacting an estimated 9-12 million hectares of wheat annually. In Germany alone, STB causes yield losses of 5-50% and costs of €1.5 billion annually, while yellow rust can reduce yields by 10-70% and even lead to total crop failure in susceptible varieties, according to recognized industry and academic sources.

Matthew Pickard, Syngenta’s Head of Seedcare and Biologicals for Europe, said: “At Syngenta, we are committed to deliver advanced, effective biological solutions at the cutting edge of science. We’re proud to work with Amoéba to offer nature-inspired solutions that empower farmers in these important markets.”

“We are very pleased with the collaboration with Syngenta, a global leader in agricultural innovation,” affirms Benoit Villers,Chaiman of the Board of Amoéba and Jean-François Doucet, CEO of Amoéba. "This agreement, which should lead to distribution and development partnerships between our two companies, is a major step forward for Amoéba. It gives us the opportunity to combine our scientific expertise with Syngenta's widely recognised leadership in cereal protection and the marketing of biocontrol solutions. Finally, it perfectly illustrates how collaboration between innovators in the sector can make a difference for farmers while paving the way for broader applications in field crops."

Founded in 2010, Amoéba has developed a patented biocontrol application based on lysate from the amoeba Willaertia magna, which received the prestigious Bernard Blum Gold Medal in October 2025 as the most promising biocontrol solution worldwide. In June 2025, the active substance received EU approval following EFSA’s scientific assessment and a European Commission decision. Product-specific authorizations are in progress.

Media Contacts  Web Resources
Syngenta Media Relations
[email protected]

Amoéba Media Relations
Pierre Jacquemin-Guillaume
Investor relations
   [email protected]

Serena Boni
Financial press relations
[email protected]

Laëtitia Pinto
Business and general public press relations
[email protected]
 Pictures

About Syngenta

Syngenta is a global leader in agricultural innovation with a presence in more than 90 countries. Syngenta is focused on developing technologies and farming practices that empower farmers, so they can make the transformation required to feed the world’s population while preserving our planet. Its bold scientific discoveries deliver better benefits for farmers and society on a bigger scale than ever before. Guided by its Sustainability Priorities, Syngenta is developing new technologies and solutions that support farmers to grow healthier plants in healthier soil with a higher yield. Syngenta Crop Protection is headquartered in Basel, Switzerland; Syngenta Seeds is headquartered in the United States. Read our stories and follow us on LinkedIn, Instagram & X.

About Amoéba

Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the treatment of microbiological risk based on the patented use of amoebae in the plant protection and cosmetics sectors.

With know-how that is unique in the world and protected by numerous patents, Amoéba is currently the only company capable of exploiting the full potential of the Willaertia amoeba on an industrial scale and cultivating it in sufficient volumes to offer biological solutions that constitute a viable alternative to the chemical products widely used today. Amoéba is currently focusing on the global biocontrol market for plant protection and on the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory authorisations, the Company has carried out the necessary regulatory procedures and filed registration dossiers in Europe and the United States. The active substance has obtained approval in 2022 in the USA and in 2025 in Europe. Product approvals have been granted in the USA and are expected in the coming months in Europe.

The cosmetic application does not require prior approval from a competent authority in Europe or the United States. The cosmetic ingredient is already registered on the INCI (International Nomenclature of Cosmetic Ingredients) list, paving the way for it to be marketed worldwide except in China, where local approval is required.

Amoéba is listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme.

For more information, visit www.amoeba-nature.com     

Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR (“legitimate interest”). However, if you do not wish to receive further information about Syngenta, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement. 

Syngenta’s Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

©2025 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.


Primary Logo

More from this category

  • General News, Medical Health Aged Care
  • 19/01/2026
  • 09:15
January 19, 2026

Concerning myopia rates amongst “indoor generation”

As we approach the 2026 school year, optometrists are encouraging parents to make outdoor play a priority for their children this school year with new data from Bupa Optical revealing that 27 per cent of Australian children who underwent an eye test last year were diagnosed with myopia. Spending time outdoorshas been proven to be beneficial for reducing myopia risk amongst children however outdoor play is on the decline with separate research noting that 50 per cent of kids reported not being allowed to play outside alone or with friends at various times. Additionally, a quarter of Aussie kids say…

  • Medical Health Aged Care
  • 19/01/2026
  • 08:30
Lanham Media on behalf of Heart Research Australia

Why Stress Is Quietly Breaking Our Hearts – and How to Reset This REDFEB

Media release Why Stress Is Quietly Breaking Our Hearts - and How to Reset ThisREDFEB With cost-of-living pressure rising in recent years, stress has become the silent epidemic of modern life - and it’s quietly breaking our hearts. Health experts warn that chronic stress is compromising how our hearts function, increasing the risk of cardiovascular disease, heart attack and even sudden cardiac events. Recent national data shows[i] that nearly half of Australians say financial worries are the biggest factor affecting their wellbeing, while more than a third of workers report feeling burnt out every week. “Most people think of stress…

  • Medical Health Aged Care, Political
  • 16/01/2026
  • 06:00
Monash University

National genomic screening program would save thousands of Australians from preventable cancer and heart disease

Leadinggenomic health experts from Monash University are calling for urgent government funding to progress the development of a national preventive genomic testing program that would save thousands of Australians from conditions like cancer and heart disease. This call to action follows a Monash-led nationwide pilot study recently completed, offering free genomic screening to 10,000 Australians aged 18 to 40. The pilot tested for 10 medically actionable genes linked to hereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolaemia. The findings are published today in the inaugural edition of the new academic journal Nature Health. The pilot study was led…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.